(Q36484553)

14 August 2017

0 references

1 reference

title

Neuroleptic drugs in dementia: benefits and harm (English)

1 reference

14 August 2017

0 references

Robert Howard

2

0 references

Clive Ballard

object named as

Clive Ballard

series ordinal

1

0 references

language of work or name

English

0 references

publication date

1 June 2006

1 reference

Nature Reviews Neuroscience

14 August 2017

1 reference

14 August 2017

7

1 reference

14 August 2017

492-500

1 reference

14 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/nrn1926

14 August 2017

0 references

cites work

Hallucinations and associated factors in Alzheimer's disease

1 reference

A follow up study of depression in the carers of dementia sufferers.

21 January 2018

1 reference

Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease.

21 January 2018

1 reference

Cholinergic deficits contribute to behavioral disturbance in patients with dementia.

21 January 2018

1 reference

Neuropathologic and neurochemical correlates of psychosis in primary dementia.

21 January 2018

1 reference

A metaanalysis of controlled trials of neuroleptic treatment in dementia

21 January 2018

1 reference

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.

21 January 2018

1 reference

A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease

21 January 2018

1 reference

Efficacy of antipsychotic medications in behaviorally disturbed dementia patients

21 January 2018

1 reference

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

21 January 2018

1 reference

Drugs and falls in older people in geriatric care settings

21 January 2018

1 reference

Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up.

21 January 2018

1 reference

Efficacy and tolerability of carbamazepine for agitation and aggression in dementia

21 January 2018

1 reference

The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease

21 January 2018

1 reference

Management of verbally disruptive behaviors in nursing home residents

21 January 2018

1 reference

A randomized trial of dementia care in nursing homes.

21 January 2018

1 reference

[Factors influencing the prescribing of nootropic drugs. Results of a representative inquiry in Lower Saxony]

21 January 2018

1 reference

Herb and supplement use in the US adult population.

31 March 2020

1 reference

Behavioral problems in dementia: a factor analysis of the neuropsychiatric inventory.

31 March 2020

1 reference

Guidelines for the management of agitation in dementia

31 March 2020

1 reference

Psychiatric phenomena in Alzheimer's disease. IV: Disorders of behaviour

31 March 2020

1 reference

Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging

31 March 2020

1 reference

Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments

31 March 2020

1 reference

A prospective study of psychotic symptoms in dementia sufferers: psychosis in dementia.

31 March 2020

1 reference

The persistence of neuropsychiatric symptoms in dementia: the Cache County Study.

31 March 2020

1 reference

A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer's disease

31 March 2020

1 reference

A 2-year follow-up of behavioural and psychological symptoms in Alzheimer's disease.

31 March 2020

1 reference

A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments

31 March 2020

1 reference

Evidence of a Monoaminergic-Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body Dementia

31 March 2020

1 reference

Delusions associated with elevated muscarinic binding in dementia with Lewy bodies

31 March 2020

1 reference

Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis

31 March 2020

1 reference

Neuropathological correlates of behavioural disturbance in confirmed Alzheimer's disease.

31 March 2020

1 reference

The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease

31 March 2020

1 reference

Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease

31 March 2020

1 reference

Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease

31 March 2020

1 reference

Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation

31 March 2020

1 reference

Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials

31 March 2020

1 reference

A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients'

31 March 2020

1 reference

A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.

31 March 2020

1 reference

Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial.

31 March 2020

1 reference

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group

31 March 2020

1 reference

Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease

31 March 2020

1 reference

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

31 March 2020

1 reference

Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study

31 March 2020

1 reference

Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies

31 March 2020

1 reference

Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration.

31 March 2020

1 reference

Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study.

31 March 2020

1 reference

Withdrawal of neuroleptic medications from institutionalized dementia patients: results of a double-blind, baseline-treatment-controlled pilot study

31 March 2020

1 reference

A 3-Month, Randomized, Placebo-Controlled, Neuroleptic Discontinuation Study in 100 People With Dementia

31 March 2020

1 reference

QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients

31 March 2020

1 reference

Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone

31 March 2020

1 reference

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

31 March 2020

1 reference

Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study

31 March 2020

1 reference

Atypical antipsychotics and risk of cerebrovascular accidents.

31 March 2020

1 reference

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

31 March 2020

1 reference

Risk of death in elderly users of conventional vs. atypical antipsychotic medications

31 March 2020

1 reference

Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication.

31 March 2020

1 reference

Neuroleptics are associated with more severe tangle pathology in dementia with Lewy bodies.

31 March 2020

1 reference

Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration

31 March 2020

1 reference

Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs.

31 March 2020

1 reference

Neuroleptic sensitivity in patients with senile dementia of Lewy body type

31 March 2020

1 reference

Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease.

31 March 2020

1 reference

Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease.

31 March 2020

1 reference

The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study.

31 March 2020

1 reference

Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease

31 March 2020

1 reference

Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

31 March 2020

1 reference

Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities

31 March 2020

1 reference

Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial.

31 March 2020

1 reference

Sensory stimulation in dementia.

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRN1926

1 reference

14 August 2017

1 reference

PubMed ID

16715057